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thought to be composed of degenerating axons and
DETECTION OF ALZHEIMER’S DISEASE AND
OTHER DISEASES USING AN IMPROVED
PHOTOAFFINITY LABELING METHOD

nerve terminals as well as possible astrocytic elements,
and they often exhibit a central amyloid protein core.

The neuro?brillary tangles are interneuronal aggregates
composed of normal and paired helical ?laments and
presumably consist of several different proteins. The

CROSS REFERENCE TO RELATED
APPLICATIONS

This application is a continuation-in-part of U.S. Ser.
No. 07/812,826, ?led Dec. 24, 1991 U.S. Pat. No.

5,272,055.
FIELD OF THE INVENTION

The present invention relates to novel compositions,

neurohistopathologic identi?cation and counting of
neuritic plaques and neuro?brillary tangles requires
staining and microscopic examination of several brain
10

sections.

It is problematic, however, that histochemical stain

ing is not always reproducible, neuritic plaques and
neuro?brillary tangles are not uniformly distributed,

methods and test kits which use the procedure of pho

and histopathologic studies are time-consuming and

toaf?nity labeling with nucleotide affinity probes, to
detect disease using cerebral spinal ?uid, blood, tissue,

labor-intensive. Moreover, there is no direct evidence
that an accumulation of abnormal cytoskeletal ?brils

or other specimens in a mammal. The present invention
provides a method of diagnosis based on a disease

speci?c biochemical marker macromolecule which, if
present, can be identi?ed in a small biological sample
from a patient. In particular, the present invention con
cerns a method for diagnosing particular disease states

using a disease-speci?c nucleotide binding protein and
detecting the binding of that protein in the serum or
cerebral spinal ?uid of a patient afflicted with that dis
ease.

BACKGROUND OF THE INVENTION

Alzheimer’s disease (AD) is an idiopathic progressive
dementia that will affect a large percentage of our aging
population. To date its etiology is still unknown. The

contributes directly to premature dysfunction and death
of the neurons; rather, the ?brils may simply be a mani
festation of more fundamental cellular changes. The
clinical and pathologic progression of Alzheimer’s dis
ease is marked by a continuing loss of neurons from the

cerebral cortex. However, neuritic plaques and neuro?
brillary tangles may occur in nondemented elderly pa
tients, as well as those af?icted with Alzheimer’s dis
ease.

Current research to develop both an understanding of
the disease and a possible diagnostic test has centered on

the amyloid protein and its precursor protein. Theoreti
cally, diagnosis has been based on the deposition of
amyloid containing plaques in the cortical region in the

brain of individuals affected with Alzheimer’s disease.
neurodegenerative disease is characterized by a chroni
Such diagnostic methods have been disclosed in, for
cally deteriorating course of impaired intellectual func
example, U.S. Pat. Nos. 4,666,829, 4,701,407, 4,816,416
tion and memory loss.
Relatively little is known of the pathophysiological 35 and 4,933,156.
However, amyloid deposits are also found in the
chain of events that leads to the premature dysfunction
brains
of aged individuals who have never displayed
and death of affected neurons in Alzheimer’s disease
signs
of
dementia. For example, a recent article (J. Biol.
patients. Multiple abnormalities have been reported in
Chem,
265:15977
(1990)) has shown that there were no
the brains of patients who have been diagnosed as hav
differences
in
the
primary structure of precursor amy
40
ing Alzheimer’s disease, but it is dif?cult to determine
loid protein from platelets of normal individuals and
which of these are the result of brain damage and which
that of Alzheimer’s disease patients. Therefore, while
contribute to premature neuronal dysfunction and
amyloid protein may be involved in Alzheimer’s dis
death.
ease, other methods have been pursued to identify char
At the present time, the clinical diagnosis of Alzhei
acteristics more uniquely related to a patient with Alz
mer’s disease is one of exclusion. Secondary causes of
heimer’s disease. For instance, U.S. Pat. No. 4,727,041,
loss of memory and impaired cognitive function may
issued to Aroonsakul, discloses a comparative test for
result from multiple infarcts, leading to so-called multi
the diagnosis of Alzheimer’s disease in humans by deter
infarct dementia, or from intracranial mass lesions, such
mining levels of somatotropin and somatomedin-C in
as subdural hematomas, brain tumors, or granulomas.
Central nervous system infections of viral and bacterial 50 the patient’s blood sera drawn at intervals following
administration of an L-dopa provocative test.
origin, or even slow viral disorders such as Creutzfeldt~
Immunoassay methods have also been developed for
Jakob disease, are part of the differential diagnosis.
detecting the presence of neurochemical markers in
Furthermore, metabolic disorders involving vitamin
Alzheimer’s disease patients. U.S. Pat. Nos. 4,728,605
B12 metabolism, thiamine or folate de?ciency, thyroid
and 4,801,533, issued to Fudenberg et al., disclose com
dysfunction, hepatic and renal failure, as well as drug
parative methods for diagnosing degenerative disease of
toxicity may appear as dementia. Nevertheless, when all
the central nervous- system, particularly Alzheimer’s
these secondary causes, many of which are reversible,
are eliminated, cerebral atrophy of unknown cause or

disease, by measuring immunological parameters and

Alzheimer’s disease still covers the largest number of

interactive T cells from a patient’s peripheral blood.
U.S. Pat. No. 4,806,627, issued to Wisniewski et at.,

patients.
The de?nitive diagnosis of Alzheimer’s disease is

made by pathologic examination of postmortem brain
tissue in conjunction with a clinical history of dementia.
This diagnosis is based on the presence in brain tissue of

discloses protease resistant proteins which comprise
scrapie-associated ?brils and a scrapie-speci?c mono

clonal antibody to distinguish certain neurological dis
ease-caused human dementias from Alzheimer’s disease.
However, none of the known methods of diagnosis

intraneuronal neuro?brillary tangles and of neuritic
(senile) plaques, which have been correlated with clini

have proven to be a reliable means of detection of A12

cal dementia. Although the cause of the abnormal cy

heimer’s disease in all patients, particularly at early

toskeletal ?brils remains unknown, neuritic plaques are

stages of the disease. As a result, alternative methods of

3
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diagnosis have been proposed which rely on analyzing

Alzheimer’s disease patients following treatment. The

the cerebral spinal ?uid drawn from the affected pa
tients. For example, Warner in Anal. Chem, 59:1203A
1204A (1987), has proposed a method for detecting
Alzheimer’s disease related amyloid protein in the cere

same can be said for other disease states, such as cancer.

Therefore, there remains a long-felt need in the art
for a reliable, accurate, safe and effective method for
the diagnosis of Alzheimer’s disease, as well as a means

for the diagnosis and differentiation of other diseases,
syndromes or pathologies. A method for the identi?ca

bral spinal ?uid of affected patients.
US Pat. No. 4,874,694, issued to Gandy et al., dis
closes a diagnostic method for neurological and psychi
atric disorders, such as Alzheimer’s disease. The
method involves incubating cerebrospinal ?uid from a
patient in the presence of 32P-labeled adenosine triphos
phate (ATP) and a protein kinase which was capable of

tion and characterization of a disease-speci?c biochemi
cal marker and the identi?cation of such a marker is
needed.
OBJECTS AND SUMMARY OF THE
INVENTION

transferring phosphate from the ATP, followed by elec
trophoresis. The resulting autoradiographic pattern of
the fractionated, labeled sample is then compared with
predetermined autoradiographic patterns from known
neurological and psychiatric pathologies to ascertain

the particular pathology of the patient’s cerebrospinal
?uid being analyzed. However, the method disadvanta
geously is based only on autoradiographic patterns. It
fails to identify disease-speci?c marker proteins in the
cerebral spinal ?uid.
Studies by Khatoon et at. (Ann. of Neurology,
26:210-215 (1989)) have shown that an interaction of an

important cellular protein, tubulin, in the formation of
microtubules was aberrant in preparations made from

15

It is, therefore, an object of this invention to provide
a method for diagnosing Alzheimer’s disease compris

ing detecting a speci?c nucleotide binding protein
within the extracted cerebral spinal fluid of patients
af?icted with Alzheimer’s disease.
It is another object of the present invention to pro
20 vide a method for diagnosing Alzheimer’s disease com

prising detecting a speci?c nucleotide binding protein
within the extracted cerebral spinal ?uid of normal
patients, but which is not photolabeled in the cerebral
spinal ?uid of patients af?icted with Alzheimer’s dis
5

ease.

It is a further object of the present invention to pro
vide a composition for use in a test kit for the diagnosis

the brain tissues of patients with Alzheimer’s disease.
of Alzheimer’s disease comprising a radioactive pho
The inhibition was monitored by measuring the interac
toaf?nity probe which will selectively bind to a speci?c
tions of a radioactive photoaf?nity probe of the nucleo 30 nucleotide binding protein within the extracted cerebral
tide GTP (guanosine-S’-tri-phosphate) with the proteins
spinal ?uid of a patient af?icted with Alzheimer’s dis
that require GTP to effect microtubule formation.
ease, but which is not found in the cerebral spinal ?uid
Molecules containing azido groups have been shown
of a normal subject.
to form covalent bonds to proteins through reactive
A still further object of the present invention is to

nitrene intermediates, generated by low intensity ultra
violet light. Potter & Haley, Meth. in Enzymol,
91:613-633 (1983). In particular, 2- and 8-azido ana
logues of purine nucleotides have been used as site di

rected photoprobes to identify nucleotide binding pro
teins in crude cell extracts. Owens & Haley, J. Biol.

Chem. 259:14843-14848 (1984); Atherton et al., Bio. of
Reproduction, 32:155-171 (1985). The 2-and 8-azido
nucleotides have also been used to map nucleotide bind

ing domains of puri?ed proteins. Khatoon et al., Ann. of
Neurologz, 26:210-215 (1989); King et al., J Biol. Chem,
264:10210-10218 (1989); and Dholakia et al., J. Biol.

Chem, 264:20638-20642 (1989).
Photoaf?nity probes have been used to determine
speci?c nucleotide binding sites on a biologically active

recombinant peptide molecule. Campbell et al., PNAS,
87:1243-1246 (1990). The probes have also been used to
study enzyme kinetics of puri?ed proteins. Kim et al., J.
Biol Chem, 265:3636-3641 (1990).

Lo) 5 provide a composition for use in a test kit for the diag

nosis of Alzheimer’s disease comprising a radioactive
photoaffmity probe which will selectively bind to a
speci?c nucleotide binding protein within in the cere
bral spinal ?uid of a normal patient, but which is not
found in the cerebral spinal fluid of a patient af?icted
with Alzheimer’s disease.
It is an additional object of the present invention to
provide antibodies to the respective Alzheimer’s disease
related proteins, as identi?ed by the method of the cur
rent invention, for the purpose of providing an immuno
assay to recognize the Alzheimer’s disease speci?c pro

teins in the cerebral spinal ?uid, blood plasma, or tissues
of the human body.
It is another object of the present invention to pro
vide a method, using the procedure of photoaf?nity

labeling with nucleotide affinity probes, to diagnose
neurological disorders using cerebral spinal ?uid,

Thus, considerable effort has been devoted to devel

blood, tissue, or other biological samples from a mam
mal. The presence or development of a neurological or

oping systems for the de?nitive diagnosis of Alzhei
mer’s disease in patients. However, until the method of

psychiatric pathology including, but not limited to,

Alzheimer’s disease, epilepsy, scrapies-type disorders,

the present invention, no reliable non-invasive test for

amyotrophic lateral-sclerosis (ALS or Lou Gehrig’s
Alzheimer’s disease has been developed. The major
disease), Down’s syndrome, Behcet disease, encephali
drawback of the most de?nitive determination of Alz
tis, Huntington disease, Creutzfeldt-Jakob disease, Par
heimer’s disease known in the art has been that direct 60 kinson disease, AIDS dementia, multiinfarct dementia,
analysis of pathological tissue could only be performed
dystonia, ataxia, schizophrenia, neurosyphilis, cerebral
postmortem on affected individuals.
toxoplasmosis, brain irradiation, brain tumor, Guillain
Because Alzheimer’s disease is progressive in nature,
Barre syndrome, tremor, multiple sclerosis, head
the ef?ciency of a cure could critically depend upon
early detection. Additionally, the value of any new
therapy in alleviating or curing the disease could be
better ascertained if a rapid, safe and effective diagnos
tic procedure were available to monitor the progress of

trauma, acute and chronic encephalitic and vascular
disease, or other disease states such as cancer or eating
disorders such as anorexia can be detected.

A still further object of the present invention is to
provide a method for aiding in the diagnosis of a spe

5
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ci?c neurological disease wherein the neurological dis
ease demonstrates elevated glutamine synthetase in the
cerebral spinal ?uid as detected by photoaf?nity label
ing with a radioactive nucleotide photoaf?nity probe,
and wherein the photoincorporation of that probe is
considerably elevated by the addition of micromolar
levels of Mn“ metal ion.

photolabeling with [32P]2N3ATP of the 42,000 M, pro
tein of cerebral spinal ?uid (3A) from Alzheimer’s dis
eased patients with that of puri?ed glutamine synthetase
(GS) (FIG. 3B). Photolabeling was done under differ
ent conditions (e. g., with or without added NH4+) and

the proteins were separated by SDS-PAGE. The 42,000
M, band was excised and the level of 321) incorporated

Yet a further object of the present invention is to
provide a method for aiding in the diagnosis of a spe
ci?c neurological disease wherein the neurological dis

was determined. Such experiments were used to show

that the 42,000 M, protein and GS behaved identically
under several different biochemical conditions and,

ease shows an elevation of one or more proteins readily

Western blotting with the GS speci?c antibody data,

observable after dialysis or ?ltration of the small mole
cules away from the proteins of CSF.
A still further object of the present invention is to
provide a method for aiding in the diagnosis of other
disease states, including non-neural disease states, such

con?rmed that the 42,000 M, protein was indeed GS.
FIG. 4 is a photograph of an autoradiograph made
from an SDS-PAGE on which human cerebral spinal

?uid proteins from Amyotrophic Lateral Sclerosis
(ALS or Lou Gehrig’s disease) or Alzheimer’s Diseased

as cancer, wherein a sample obtained from a patient
suffering from that disease shows an elevation or a de
crease in one or more proteins that are detectable by

photoaffinity labelling.

6

FIG. 3 shows two bar graphs which compares the

20

Additional objects, advantages and novel features of
the invention will be set forth in part in the description
which follows, and in part will become apparent to
those skilled in the art on examination of the following
description, or may be learned by practice of the inven
tion.

(AD) patients were separated after photolabeling with
[32P]8N3ATP or [32P]8N3GTP. This autoradiograph
shows that neither [32P]8N3ATP or [32P]8N3GTP de
tects the AD speci?c 42,000 M, protein in the cerebral
spinal ?uid of patients with ALS. This further con?rms
the selectivity of this approach as a diagnostic test for

AD. However, using [32P]8N3GTP a protein of about
55,000 M, is photolabeled in only the ALS cerebral
spinal ?uid. Further tests indicate that this protein is
only found in the cerebral spinal ?uid of ALS patients
and is probably diagnostic of this disease.
FIG. 5A is an SDS-PAGE gel showing pure GS.
FIG. 5B is an autoradiograph of the SDS-PAGE gel of

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a photograph of an autoradiogram made

from a sodium dodecyl sulfate-polyacrylamide gel

FIG. 5A which shows that the presence of Mn2+

(SDS-PAGE) on which human cerebral spinal ?uid
proteins were separated after being photolabeled with
[32P]8N3ATP. The cerebral spinal ?uid samples were
obtained from patients known to have epilepsy (lanes

greatly enhances the photolabelling of GS by

[32P]8N3ATP.
FIG. 6A is an SDS-PAGE gel demonstrating
photolabeling of two samples from patients in an early

E), Parkinson’s disease (lanes P), Alzheimer’s disease
(lanes AD) or from normal, age-matched control sub

stage of AD. FIG. 6B is an autoradiogram of the gel
from FIG. 6A showing the enhancement of photolabel
jects (lanes N). The autoradiograph shows that a pro
ing of GS and four other proteins in these samples by
tein of about 42,000 M,is photolabeled only in the cere
bral spinal ?uid of a patient with Alzheimer’s disease. 40 Centricon ?ltration.
FIG. 7 is an autoradiograph made from an SDS-PAG
Also, the selectivity of this interaction with naturally
on which photolabeled proteins from blood serum of
occurring ATP is demonstrated by the prevention of
normal, sickle cell anemia and cancer patients were
photolabeling by [32P]8N3ATP when ATP is present as

separated.
shown in the last four lanes.
FIG. 8 is an autoradiograph made from an SDS-PAG
FIGS. 2A and 2B is a photograph of two combined 45
on which photolabeled proteins from blood serum of
autoradiographs of the two 10% SDS-PAGE shown in
normal and cancer patients were separated subsequent
FIGS. 2 C and D on which human cerebral spinal ?uid
to spin ?ltration. Signi?cant changes were observed in
proteins were separated after photolabeling with
the level of photolabelling of several proteins especially
[32P]8N3cAMP. These are the same patient samples
those below 40,000 M, values.
used in FIG. 1. Samples were from patients with epi
lepsy (lanes E), Parkinson’s disease (lanes P), Alzhei

DETAILED DESCRIPTION OF THE
PREFERRED EMBODIMENTS OF THE
INVENTION

mer’s disease (lanes AD), or from normal control sub

jects (lanes N). The lane labeled “markers” contained
proteins of known molecular weight which were used

to determine the approximate molecular weight (M,
value) of the cerebral spinal fluid proteins. The SDS

55

In accordance with the present invention, novel com
positions, methods and test kits are provided, using the

PAGEs were stained with Coomassie Brilliant Blue R

procedure of photoaf?nity labeling with nucleotide

(CBB) to detect cerebral spinal ?uid proteins of differ

affinity probes, to detect a neurological disorder using
cerebral spinal ?uid, blood, tissue, or other biological

ent M,values and are shown in FIGS. 2 C and D. Prote

ins photolabeled with [32P]8N3cAMP, since they are
now radioactively tagged, were located by autoradiog
raphy as shown in FIGS. 2A and 2B. The data in the
autoradiographs of FIGS. 2A and 2B show that a pro
tein of about 68,000 M, is photolabeled only in the cere

samples from a mammal. The presence or development
of a neurological or psychiatric disorder can be de
tected. The invention concerns a composition, the prep

aration of the composition and a method for diagnosing
or detecting Alzheimer’s disease. The method involves
bral spinal ?uid of normals, epileptics and Parkinson’s 65 the use of a disease-speci?c nucleotide binding protein
within the extracted cerebral spinal ?uid of a patient
diseased individuals. This 68,000 M, protein is not
af?icted with a neurological disorder such as Alzhei
photolabeled in the cerebral spinal ?uid of Alzheimer’s
mer’s disease.
diseased patients.

7
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The present invention provides a method for detec
tion using a disease-speci?c biochemical marker macro
molecule which, if present, can be identi?ed in a small

The ?nished gel is placed in a holder containing
X-ray ?lm for autoradiography. The radioactive pro
tein (the result of chemical crosslinking between the

biological sample obtained from a patient. The speci?c

radioactive photoprobe and the binding protein) in the

biochemical marker macromolecule is dependent on the 5 gel can be located since the radioactivity will expose the
disease state which is being detected.
adjacent section of the ?lm resulting in a darkened

The standards for testing for neurological disease
(black) appearance.
states are established by obtaining cerebral spinal ?uid
The sample subjected to analysis can be selected from
samples from a number of patients, each of whom suf
any biological sample capable of carrying the unique
fers from a particular disorder which is clinically mani 10 nucleotide binding protein. Examples of such biological
fested by marked dementia or de?ciency in cognitive
samples include body ?uids such as spinal ?uid, blood
function, including memory or attention.
or serum. However, samples tested for the unique nu
Speci?cally the neurological diseases of the nervous
cleotide binding protein by the present method are most
system, referred to in the method of the present inven
preferably cerebral spinal ?uid, also referred to as cere
tion are those diseases, disorders, or syndromes which

brospinal ?uid or serum.

are either the cause of or the result of a biochemical

The protein composition of cerebral spinal ?uid is

alteration in the brain, brain stem, spinal cord or gan
glia. The diseases can include, but are not limited to,

largely derived from serum proteins which leak into the
subarachnoid space through imperfections in the blood

Alzheimer’s disease, epilepsy, scrapies-type disorders,

brain barrier, such as the area postrema, and perhaps

amyotrophic lateral sclerosis (ALS or Lou Gehrig’s 20 across the richly vascular choroid plexus, through

disease), Down’s syndrome, Behcet disease, encephali
tis, Huntington disease, Creutzfeldt-Jakob disease, Par
kinson disease, AIDS dementia, multiinfarct dementia,

which cerebral spinal ?uid is generated as an ultra?l

dystonia, ataxia, schizophrenia, neurosyphilis, cerebral
toxoplasmosis, brain irradiation, brain tumor, Guillain
Barre syndrome, tremor, multiple sclerosis, head

25

trauma, acute and chronic encephalitic and vascular
disease. Moreover, the present method of detection

trate. The cerebral spinal ?uid has signi?cantly fewer
proteins than cytosolic fractions. Some proteins, such as
immunoglobulins, may be generated in the subarach
noid space during in?ammation. Since the cerebral
spinal ?uid bathes the surfaces of cerebral and cerebel
lar cortices, the caudate, brain stem and spinal cord,
each of the structures contributes to the total cerebral

could also be used to monitor any event which causes

spinal ?uid protein.

brain cell death which results in the accumulation of 30

The inventive method need not be limited to human
patients, but may be extended to any mammal af?icted

nucleotide binding proteins in the cerebral spinal ?uids,

such as, minor to severe brain damage caused by high
with certain diseases or syndromes, including scrapies
fever or head injury. The present invention can also be
or “Mad Cow” disease.‘
utilized to detect other disease states such as cancer,
The sample may be drawn as either ventricular cere
which also lead to alterations in the level of biochemical 35 bral spinal ?uid or as lumbar cerebral spinal ?uid, or as
marker macromolecules.
a blood sample. Occasionally, however, sample proteins
By the present invention it has been shown that a
are concentrated by various procedures to better visual

disease-speci?c unique biochemical marker macromole
cule, in particular a speci?c nucleotide binding protein,

ize the speci?c nucleotide binding protein. Vacuum
procedures include, for example, lyophilization or
can be identi?ed in the spinal ?uid of patients suffering 4-0 Speed-vac concentration. Also, precipitation of cere
from certain neurological disorders, particularly pa
bral spinal ?uid by ammonium sulfate or polyethylene
tients suffering from Alzheimer’s disease. Additionally,
glycol could be used to concentrate the nucleotide bind
it has also been shown that proteins obtained from ?uid
ing proteins. Thus, there are a variety of techniques
samples from cancer patients show altered photolabel

ing compared to normal patients.
Brie?y, a typical analysis of a cerebral spinal ?uid
sample or serum by the method of the present invention
would proceed as follows. These steps and quantities
are only offered as guidelines for the practice of the

well known in the art that would be suitable in the
45

practice of the present invention.
Detection of a speci?c nucleotide binding protein can
be accomplished by measuring a label crosslinked to the
selected biochemical marker macromolecule after reac

tion, photochemical or chemical crosslinking, and re
present invention.
moval of free probe. The particular label bound to the
A small portion, usually between 10 to 30 microliters
macromolecule will include, for example, a radioactive
of cerebral spinal ?uid or serum is mixed with concen
nucleotide introduced by replacing an equivalent non
trations of about 10 to 30 uM of a radioactive radioaf
radioactive atom with 32P, tritium, carbon-l4 or other
finity probe for 0.5 to 1.0 minutes, followed by 30 to 120
radioactive atom or ligand analog modi?ed with a
seconds of exposure to ultraviolet light. Photoincorpo 55 linker group to provide a linking site to the crosslinking
ration of [32P]8N3ATP into GS is preferably elevated
molecule. A particularly preferred radioactive label in
by the addition of micromolar levels of Mn2+ metal ion.
the present invention is a- or 'y-32P.
Suitable levels of Mn2+ metal ion range from 1.0 uM to
The ligand or linker group, if present on the speci?c
1000 uM, more preferably 5 nM to 50 p.M, and most
biochemical marker macromolecule, will have chemical

preferably 10 pM. The sample is precipitated, then
immediately solubilized with a solution containing de
tergent and subjected to protein fractionation, such as

by gel electrophoresis. In a preferred embodiment,

60 characteristics or functionalities such that a small radio

active nuclide labeled molecule, or a chromogenic,
?uorogenic, or luminescent molecule, or a magnetic
particle can be attached to the ligand or linker group.

prior to photolabeling, CSF or serum samples are ?l
The ligand will have the chemical characteristics such
tered by dialysis or ?ltration using a ?ltration device 65 that a receptor molecule is available or capable of being
such as a Centricon ?lter. Such ?ltration or dialysis
elicited, such as an antibody molecule to the ligand. The
removes small molecules from the CSF or serum which
receptor molecule can be conjugated to a radioactive
interfere with photolabeling.
nuclide labeled molecule, or to a chromogenic, ?uoro

9
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chromogenic, ?uorogenic, and/or luminescent product

a pathway for the synthesis of other useful 5-substituted
uridine nucleotides. The S-diazouridine nucleotides
may, for example, serve as active-site-directed photoaf
?nity probes or as substrates for polymerizing enzymes
to generate additional photoactive nucleic acids which

via appropriate substrates.
Most preferably the unique biochemical marker mac

romolecule, particularly the speci?c nucleotide binding
protein, is detected in the sample by a radioactively
labeled photoaf?nity probe. A nucleotide photoaf?nity

remain stable to extremes of pH and which remain ef
fective photolabeling reagents in the presence of reduc

probe is a nucleotide derivative which has affinities for

binding sites and biological activity comparable to the
unaltered nucleotide. Exposure to certain wavelengths

ing agents. Moreover, since the synthesis of S-NgdUTP
employs mild conditions, it is also possible to synthesize

of light converts the analog to a very reactive interme
diate, typically a nitrene or a carbene, which may result
in covalent incorporation into the binding site if it is
bound to a protein.

homopolymers of 5-N3dUTP to provide single-stranded
photoactive DNA of de?ned length. Using 5N3UTP
15 one can similarly produce photoactive RNA.

Generalized methods for the synthesis of aryl azides
include nucleophilic displacement of a bromine, chlo

There are certain advantages to using photoprobes
over conventional chemical probes. One advantage is
that Km, Kd, and K,- values can be determined in the

rine or nitro group by an azide ion or the addition of
sodium azide to an acidic solution containing a diazo

absence of activating light. Another advantage is that
complex systems such as ribosomes, membranes, and

tized primary aromatic amine.
To date the most widely used 8-azidopurine is proba
bly 8N3cAMP. One of the advantages of 8N3cAMP is

whole cell sonicates can be studied. In this manner, an

in vivo situation may be more closely approximated and
information may be obtained that might otherwise be
lost in a puri?ed system.

Many nucleotide photoaf?nity probes may be synthe

10

derivatives. For instance, photoactive analogs of dUTP,
such as 5-azido-2'-deoxyuridine 5’-triphosphate (5
N3dUTP), may be synthesized from dUMP and provide

genic, or luminescent dye molecule, or to a magnetic
particle or to an enzyme system capable of generating a

that in mammalian systems there are only two types of
proteins that are known to bind cAMP with high affm
25

sized and used successfully. The photoaf?nity com
pounds of the invention may include, for example, pu

ity, the cAMP phosphodiesterases and the regulatory
subunits of the cAMP-dependent protein kinases. The

photoprobes [32P]8N3cAMP and [32P]8N3ATP have

line triphosphate azido analogs, which may be exempli
?ed by adenine analogs, although guanine analogs can
be substituted therefor. For example, purine binding
sites may be effectively labeled by the following, and
their 5'-mono-, di- and triphosphates: oligomers of a
single azidoadenylyl species, such as, for example: 2
azido or 2-azidoadenylyl(2’-5’)2-azidoadenylyl(2'-5')2

been employed to study, for example, the mechanisms
of action of cAMP-dependent protein kinase. Photoac
tive analogs of GTP, e.g., [32P]8N3GTP, have been
developed to study, for example, tubulin polymeriza

azidoadenosine; 2-azido or 8-azidoadadenosine; 8 35

Preferred compounds of the present invention are
synthesized from azidoadenosine 5’-triphosphates or

tion, while photoactive analogs of UTP, e.g.,
[32P]5N3dUTP have been generated to study, for exam

ple, the binding site of DNA binding proteins.

azidoadenylyl(2’-5')-8-azidoadenylyl(2’-5’)8
azidoadenosine;
8-azidoadenylyl(2’-5’)-8

combinations thereof, which provide a (2'-5’)oligomer

azidoadenylyl(2’-5’)8-azidoadenylyl-(2'-5’)8

containing both adenylyl and azidoadenylyl moieties. A
preferred photoaffmity compound for the identi?cation

azidoadenosine;
2,8-diazidoadenylyl(2’-5’)2,8
diazidoadenylyl(2’-5')2,S-diazido-adenosine;
2,8
diazidoadenylyl(2'-5’)2,8-diazidoadenylyl(2'-5')2,8

by the present invention of the Alzheimer’s disease

diazidoadenylyl(2'-5')2,8-diazidoadenosine; also oligo

speci?c protein is 8-azidoadenosine 5'-triphosphate
(8N3ATP), while a particularly preferred photoaf?nity

mers of AMP and a single azidoadenylyl species, such

compound of the present invention is 2-azidoadenosine

5'-triphosphate (2N3ATP). A particularly preferred

as, for example: 2-azidoadenylyl(2’-5’)2-(2’-5’)adeno

sine; adenylyl(2’-5’)8-azidoadenylyl(2’-5’)8-azidoadeno

45

sine; also oligomers containing more than one azidoade

photoaf?nity compound for the identi?cation by the
present invention of the ALS-speci?c protein is 8

nylyl species, such as, for example: 2-azidoadenylyl(2'

azidoguanosine 5'-triphosphate (8N3GTP). Particularly

5’)8-azidoadenylyl(2’-5')2-azidoadenosine; also oligo

preferred photoaf?nity compounds for the identi?ca
tion by the present invention of the cancer-speci?c
proteins
are
8-azidoadenosine
5'-triphosphate
(8N3ATP) and 2-azidoadenosine 5’-triphosphate

mers resulting from any combination of the monomers

AMP, 2-azido-AMP, 8-azido-AMP and/or 2,8-diazido
AMP, provided that at least one such monomer incor

porated into the oligomer is an azido-AMP species.
In addition photoaf?nity compounds of the invention
may also include photoactive coenzyme analogs of

NAD+, exempli?ed by nicotinamide 2-azidoadenosine
dinucleotide (2-azido-NAD+), or analogs of NADH,

exempli?ed by nicotinamide Z-hydrazidoadenosine di
nucleotide (2-azido-NADH).
Alternatively, guanine moieties can be de?ned in
each of the exemplary compounds in place of the re
spective adenine moieties. Therefore, certain most pre
ferred compounds of the present invention are synthe
sized from azidoguanosine 5'-triphosphates or combina
tions thereof, or from azidoguanosine 5'-triphosphates
and ATP. The latter provides a (2'-5’)oligomer contain 65

ing both guanylyl and azidoguanylyl moieties.
Furthermore, photoaf?nity compounds of the present
invention may also include, for example, pyrimidine

(2N3ATP).
Nonradioactive labels can be divided into two cate

gories (i) chromogenic, ?uorogenic, or chemilumines
cent dyes or (ii) ligands. Dyes are normally of from 8 to
40 carbon atoms, preferably from 9 to 30 carbon atoms.
The dyes further normally contain from 1 to 10 hetero~
atoms usually oxygen, nitrogen, or sulfur, and normally
contain no halogen atoms or up to 10 halogen atoms

usually iodine, bromine, chlorine, or ?uorine.

Chromogenic dyes may include phenol sulfoneph
thalein and analogs of tetrazolium.

Fluorogenic dyes may include ?uorescein isothiocya

nate, dichlorotriazinylamino ?uorescein, morpholinor
hodamine isothiocyanate, tetramethylrhodamine isothi
ocyanate, and 4-acetamido»4-isothiocyano-stilbene-2
with 2’-disulfonic acid. Fluorescent purine derivatives
may also include, for example, the ?uorescent GTP
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2'3’-O-(2,4,6-trinitrocyclohexadienyl-idine)

guanosine 5'-triphosphate (TNP-GTP), or the equiva
lent ?uorescent ATP derivative (TNP-ATP).
Chemiluminescent dyes may include 5-amino-2,3

dihydro-phthalazine-1,4-dione (luminol), derivatives of

12

determination of concentration is the stability of the
reagent. The stability of the reagent can be determined
by thin-layer chromatography, e. g., by ?uorescent cel

lulose thin-layer chromatography.
5

Ionic strength, pH, cofactor, and metal ion concen

isoluminol and acridinium esters.

trations can each affect protein structure, and are

Any ligand may be employed for which an appropri
ate receptor may be found to have satisfactory specific

readily adjusted by those skilled in the art to achieve

ity for the ligand.

poration of the photoaf?nity probe 8N3ATP into GS is
preferably elevated by the addition of micromolar lev
els of Mn2+ metal ion. In addition protein concentration

optimal labeling conditions. For example, photoincor

Various methods or protocols may be employed in
measuring the amount of the labels. These protocols can

include for example, radioimmunoassay (RIA), im

can be determinative of the photoresponse. Also, both

munoradiometric assay (IRMA), sandwich IRMA,
?uoroimmunoassay (FIA), chemiluminescent assays,

ammonia and glutamate (co-substrates) enhance
photolabelling if Mg2+ or Mn2+ is present. The higher
the protein content of the sample, the denser the solu

bioluminescent assays, and enzyme linked immunosorb
ent assays (ELISA) among others.
The labeled probe of the present invention can be

tion becomes to light. Therefore, in a denser solution,
less UV light reaches the photoreagent per unit of time,

used in any conventional hybridization technique. Hy

decreasing the rate of photoincorporation. Aggregation

bridization formats which may be useful in the practice
of the protein can also affect the binding time of the
of the present invention include those in which the 20 reagent to the protein, thereby increasing or decreasing
sample is immobilized on a solid support (solid-phase
photoincorporation. One must experimentally redeter
hybridization) and those wherein the species are all in
mine optimal photolysis time when changing protein

solution (solution hybridization). Solution hybridization
concentration if maximum incorporation of the photola
is preferred in the present method. Another method of
bel is desired.
interest is the sandwich hybridization technique.
25
By the present invention, it is preferable to photolabel
Certain factors are considered when a unique bio
chemical macromolecular marker is identified by means
of a radioactive photoaf?nity label, as is the preferred

' a small 10 to 30 microliter aliquot of cerebral spinal ?uid

method of the present invention. For example, consider
ation should be given to: (a) temperature of incubation

mate ?nal concentration of 10 to 30 uM for detection of

and photolysis, (b) length of incubation and photolysis,
(0) concentration of photoaf?nity reagent, (d) binding
affinity of protein for the reagent and natural ligands,
(e) stability of the photoaf?nity reagent in each particu
lar system, (f) ionic strength, pH, cofactors, (g) protein

concentration, (11) intensity of photolyzing light, (i)
quenching of reaction and separation of unused label,
and (i) interpretation of results. Potter & Haley in Meth.
in Enzymol, 91:613-633 (1983) provide a detailed ac
count of preferred procedures for labeling a speci?c

with radioactively-labeled photoaf?nity probe (i.e.,
[32P]2N3ATP or [32P]8N3ATP) resulting in an approxi

the Alzheimer’s disease-speci?c 42,000 M, protein.
Most preferably, the aliquot of each cerebral spinal ?uid
analyzed is 15 ul. However, limits of detection are im

proved, at little expense, by using larger sample vol
umes or by concentrating the spinal ?uid.

‘

In the alternative, the sample may be labeled with
[32P]8N3cAMP, in which case the sample is placed on
ice to reduce the temperature to about 0° C. and photo
activated. In experiments conducted to evaluate the
absence of [32P]8N3cAMP photoinsertion into the pro
40 tein of interest in a cerebral spinal ?uid sample, the

biochemical marker macromolecule in a sample with a

preferred concentration of [32P]8N3cAMP is main

photosensitive purine triphosphate azide analog.

tained at not more than 5 uM.
Detection of the labeled protein occurs following an

Temperature of the photolysis reaction between the

sample and the selected photoaf?nity label can range
appropriate, predetermined incubation time to effect a
from 0° C. to room temperature (25° C.) or above. How 45 reaction, and is calculated on the basis of the sample and
ever, the exchange rate between bound and unbound
the selected photoaf?nity probe.
cAMP or 8-N3cAMP approaches negligible levels at 0°
The intensity of the photolyzing light is such that
C., and is greatly increased at room temperature. Con
maximum photoincorporation can be obtained in a mini
versely, once 8-N3cAMP is bound to the speci?c mac
mum amount of time without appreciable change in
romolecular marker, it may be cold trapped onto the
temperature or damage to the biological sample. Prefer~
protein by dropping the temperature to nearly 0° C.
ably the photolysis is achieved at 254 nm with an ultra
Therefore, the most preferred procedure includes prein
violet light source.
cubation of the components at room temperature, and
Ultraviolet (UV) light is essential for the activation of
photolysis in plates set on ice to reduce the temperature
the photoprobe treated samples, but only a low intensity
to approximately 0° to 4° C. By the present invention, 55 UV light is necessary. The intensity of the UV light can
the sample is preferably incubated at room temperature
range from 180 to 800 nW/cm2 by conventional sources
with the radioactive photoaf?nity probe for approxi
to 4000 p.W/cm2 and above when a high intensity
mately 0.5 to 1.0 minutes. Most preferably the mixture is
source is used to achieve rapid photolysis.
vortexed for 6 seconds followed by an additional 24
Photolysis times range from 15 seconds to 5 minutes
seconds of mixing, immediately followed by placing the 60 and must be experimentally determined for each reac
sample on ice for photoactivation.
tion system. For lamps having intensities of 180-800
The concentration of photoaf?nity reagent must be
uW/cmZ, the preferred photolysis time ranges from

compatible with the binding affinity of the protein to be
labeled. Excessively high concentrations, however, can
lead to undesirable nonspeci?c labeling which increases

approximately 30 to 120 seconds, most preferably, pho
tolysis is effected in approximately 30 to 60 seconds.

by experimentally determining the optimum concentra

The distance of the light source from the sample is a
determinative factor in the conditions of photolysis. A
preferred method of the present invention uses an ultra

tion for photoincorporation. Directly related to the

violet light source having suf?cient intensity, about

linearly with concentration. Best results can be obtained

65
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Support materials could include, e.g., polyacrylamide

6200 ].LW/Cm2, positioned at a set distance, about 1 cm
from the sample, for a time suf?cient to effect photoac

gels, ?lter paper, starch gels or blocks, cellulose or

tivation, generally approximately 45 seconds.
The labeled macromolecule is typically separated

polyurethane foam. Any effective, known method of
protein separation may be used, but preferably separa

from the solution containing excess unbound sample

tion is by electrophoresis over denaturing or non
denaturing gels, or over a gradient of either type. In the

and/or label by precipitation, although other recog
nized methods of protein puri?cation are possible. Rec

present method, protein separation is usually by electro
phoresis on a denaturing gel.
The nature of the sample and the size of the speci?c
nucleotide binding protein determine the concentration
of the gel used, which in turn determines the time for
separation and the electrical current which must be

ognized methods of precipitation include, but are not
limited to addition of an effective protein precipitating
agent, such as trichloroacetic acid (TCA), perchloric

acid (PCA), acetone, ammonium sulfate polyethylene
glycol (PEG) or the like to the sample. PCA or ammo
nium sulfate are the preferred precipitating agents in the

applied to best achieve protein separation. The protein

present method, and PCA is the particularly preferred

precipitating agent.

15

The amount of precipitating agent is determined by
the concentration of protein in the sample. The pre
ferred concentration of the precipitating agent is that
concentration which effectively precipitates the spe
ci?c protein from solution. The most preferred concen
tration of the precipitating agent is that amount which

effectively precipitates the previously activated,
photolabeled cerebral spinal ?uid sample.
The precipitating agent can be mixed with the sample

fractions of the present invention most preferably may
be separated by electrophoresis on an SDS-polyacryla

mide gel (SDS-PAGE) or by isoelectric focusing (IEF)
or on two dimensional systems (IEFXSDS-PAGE).

Typically, the sample is fractionated on a 10% poly
acrylamide gel, run over a period of 2% to 3 hours, with
constant amperage of 35 mA and an initial voltage of

about 140 volts. Any standard electrophoresis equip
ment can be utilized.

The resultant gels are exposed to X-ray film and

visualized by autoradiography according to methods

as a dry batch addition or in a calculated equivalent 25 well known in the art. The gels can also be stained to

liquid form. The required mixing time may vary with

determine the presence of the unique speci?c protein

the nature of the agent selected and the size or concen

band or to ascertain that differences in the amount of

tration of the sample. However, the time required is that
point after which essentially no additional protein is
precipitated from the sample solution at the tempera

in the protein levels. Many known protein staining

ture selected.

liant Blue R (CBB) or silver staining. CBB is a com
monly used stain that detects proteins based on a hydro

The precipitated protein may be separated from solu
tion by any effective means, such as centrifugation,

sedimentation or ?ltration. A preferred method of sepa

photolabel incorporation are not due to drastic changes

methods are widely recognized, e.g., Coomassie Bril

phobic interaction between the proteins and the dye.
Although any available staining method can be used

ration of the precipitated protein from the solution is by

which effectively distinguishes the speci?c nucleotide

centrifugation at a suf?cient speed and for a sufficient
time to effectively isolate the protein into a pellet, for

binding protein, CBB is the fastest and most economical
for the present method.

Most preferably, each completed SDS~PAGE gel is

example by centrifugation at 13,000XG for 30 minutes.
However, the parameters vary with the nature of the

stained with an effective amount of CBB to stain the

solution.

selected protein fragments. However, many times pro

’ '

To determine the effectiveness of the precipitation
and separation procedures, both the pellet and the su

teins can be detected by photolabelling that cannot be

pernatant ?uid are analyzed for protein content.
The precipitated protein may be solubilized and any

lar, the completed gel is immersed in a 10% CBB (W/v)

remaining reaction quenched by any effective, known
method. The determination of the solubilizing agent

45 solution to effectively remove excess stain. Particularly

detected by any protein staining procedure. In particu
solution for about 1 hour. Then the gel is destained in a

preferred is a destaining solution of 5% acetic acid and

would depend on the ultimate method of identifying the

10% isopropyl alcohol applied for 10418 hours.

speci?c nucleotide binding protein. Therefore, such

Finally, the speci?c binding protein fragments may
be visualized by standard autoradiography techniques.

agents could include, e.g., sodium dodecyl sulfate
(SDS) or urea, and certain stabilizing agents.
Any azide remaining after photolysis may be de
stroyed by the addition of dithiothreitol or its equiva

The use of an intensifying screen effectively accelerates

the visualization process of autoradiography. By the
method of the present invention, the stained gel is dried,

and then exposed to DuPont Cronex 4 X-ray ?lm. The
autoradiographic procedure is for variable time periods
phate derivative N3ATP or N3GTP may be inhibited
by chelators such as EDTA. The preferred protein 55 depending on the speci?c activity of the probe photoin
serted into the proteins of each experimental sample.
solubilizing agent is a detergent, particularly SDS, most
Alternately, if maintained at —70° C., the gel can be
preferably in a protein solubilizing mix (PSM), such as
subjected to autoradiographic procedures while still in
described by Potter & Haley in Meth. in Enzymol,
the gel state.
9lz6l3~633 (1983) or by procedures standard to most

lent, and potential phosphotransfer from the triphos

published procedures. A particularly preferred concen

The amount of protein, as well as the radioactivity

tration of SDS in the mix is 10%, resulting in a concen
tration of SDS to the ?nal sample of 4%.

incorporated into each protein, can be quanti?ed by

Solubilization can occur either at 0° C. or at higher

known methods including, but not limited to, densito
metric scans of the exposed X-ray ?lm, or of the stained

temperatures without affecting the results. However,

gel, or by liquid scintillation spectrometry of the protein

solubilization in the present invention is effective at 65 band following excision from the gel.
room temperature.

Upon solubilization, the protein sample is applied to a
suitable support for separation of the protein fractions.

Analyses of cerebral spinal fluid taken from human
patients suffering from certain neurological or psychiat
ric diseases or disorders, when labeled with the appro

5,445,937
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priate, subsequently activated, radioactive photoaf?nity

with a GTP analog, con?rm the results observed when

probe, reveals a disease-speci?c biochemical marker by
For example, a protein band having an apparent molec
ular weight of about 68,000 Dil0% is found in the
cerebral spinal ?uid of normal human subjects, visual
ized by a subsequently activated, radioactive photoaf

the 42 kD protein is photo-labeled with the photoaf
fmity probe of ATP.
Based on mixing experiments of cerebral spinal ?uid
taken from control subjects (in which the 68 kD protein
is photolabeled) and samples of Alzheimer’s disease
patients’ cerebral spinal ?uid (in which the 68 kD pro

fmity probe, e.g., [32P]8N3cAMP. More particularly,

tein does not photolabel), it may be shown by the pres

which an existing disease state can be characterized.

the identi?ed protein band has an approximate molecu
lar weight of 68 kD. Moreover, a fragment of the same

ent invention that a component of the Alzheimer’s dis

ease cerebral spinal ?uid apparently prevents photola
beling of the 68 kD protein of normal, control sample
cerebral spinal ?uid with [32P]8N3cAMP.
By the present invention, the Alzheimer’s disease
specific 42,000 M, protein could be further identi?ed as

size is recognized in cerebral spinal ?uid samples taken
from patients afflicted with neurological diseases other
than Alzheimer’s disease.

By comparison, the cerebral spinal ?uid of human
patients suffering from Alzheimer’s disease, is charac
terized by an absence of photodetection of the protein
fragment having an approximate weight of 68 kD, as

visualized by

photolabeling by,

for

example,

[32P]8N3cAMP (see FIG. 2).

15

glutamine synthetase. Mammalian glutamine synthetase
is an enzyme with 42,000 M, subunits that catalyzes the

following reaction:
glutamate+NH4+ATP—>glutamine+ADP+ P,

Furthermore, the cerebral spinal ?uid of human pa

tients suffering from various neurological and psychiat

Further, it has been suggested that metabolism of gluta

mate is altered in Alzheimer’s disease (AD) since those
sections of the diseased brain which have become dys
functional show very low levels of glutamate. More
a distinctive means of diagnosing particular diseases. 25 over, the neuronal cells that die in Alzheimer’s disease
patients are glutamate sensitive cells.
For example, a characteristic protein band having an
Glutamine synthetase can also be detected by measur
apparent molecular weight of about 42,000 Dil0% is
ing the enzymatic catalytic conversion of substrates to
found in the radioactive photoaf?nity labeled cerebral

ric disorders, labeled with a subsequently activated,

radioactive photoaf?nity probe, is found to have unique
speci?c nucleotide binding proteins which can provide

products. Recognized detection techniques include, for
spinal ?uid of Alzheimer’s disease patients using
[32P]8N3ATP. More particularly, the Alzheimer’s dis 30 example, measuring the catalytic conversion of
ease-speci?c identi?ed protein band has an approximate
[14C] glutamate to [14C]glutamine or [a32P]ATP to [a32
molecular weight of 42 kD.
P]ADP. Such methods of measuring catalytic conver
By comparison, a systematic survey of the cerebral
spinal ?uid taken from normal human subjects and la

sion are applicable to the detection of the Alzheimer’s

disease-speci?c 42,000 M, protein of the present inven

beled with a similar subsequently activated, radioactive 35 tion.
The 42,000 M,protein is present in the cerebral spinal
?uid of Alzheimer’s disease patients in very small quan
tities. However, other than albumin and a protein of
unique to Alzheimer’s disease patients. There is appar
about 28,000 M,, the 42,000 M, protein is the major
ently no identi?ed corresponding protein fragment con 40 protein known to photolabel with either 8N3ATP or
tained in the cerebral spinal ?uid of normal human
2N3ATP at the concentrations used. Therefore, by

photoaf?nity probe (i.e., [32P]8N3ATP), shows no pro
tein fragment having an approximate weight of 42 kD
being photolabeled. Thus, the identi?ed protein is

subjects.

using the technique of photoaf?nity labeling and the

In addition to being photolabeled with the radioac
materials and methods of the present invention, it is
possible to detect a very minor protein of cerebral spi~
tive photoprobe, the 42,000 M, protein may be shown to
interact with ATP, a naturally occurring nucleotide 45 nal ?uid that interacts with ATP and GTP, and which
appears to be unique in the cerebral spinal ?uid of clini
that is the phosphate donor for many protein kinases

and synthetases (last four lanes_FIG. 1). Therefore,

cally diagnosed Alzheimer’s disease patients.

Also important for the diagnosis of other disease
based on the selectivity, the Alzheimer’s disease
states is the dramatic appearance of other smaller mo
speci?c protein may be identi?ed as an ATP binding
protein of about 42,000 M,. Furthermore, the same 42 50 lecular weight proteins that photolabel only after ?ltra
tion. One of these small proteins is tumor necrosis factor
kD protein can be photolabeled with 8-azido-GTP,
(TNF) which is proposed to be elevated in several dis
de?ning the speci?c protein as an ATP and GTP bind
ease states, including ischemia and AD. Also present is
ing protein. However, the 42,000 M, protein binds ATP

with higher affinity.
Therefore, the human cerebral spinal ?uid samples

acidic ?broblast growth factor (aFGF). Studies with
55 several different CSFs from neurological diseases show

that these proteins change dramatically in different
can be reliably and accurately distinguished into two
disease states.
groups. The cerebral spinal ?uid samples taken from
Other biological response modi?ers (i.e., cytokines,
Alzheimer’s disease patients show photoinsertion of
growth factors, etc.) reportedly in this lower molecular
[32P]8N3ATP or [32P]2N3ATP into the identified dis
ease-speci?c 42 kD protein, but an absence of photoin 60 weight region of CSF ?uids include nerve growth fac~
tor (NGF), interleukin-1 (IL-1), interleukin-2 (IL-2),
sertion of [32P]8N3cAMP in the normal 68 kD protein.
and basic ?broblast growth factor (bFGF). Fluid levels
Whereas, the samples taken from control subjects, unaf
of each of these factors have been postulated to be in
?icted by Alzheimer’s disease, show photoinsertion of
volved in various disease states. Each of these biological
[32P]8N3cAMP into a normal 68 kD protein, but no
photoinsertion of either [32P]8N3ATP or [32P]2N3ATP 65 response modi?ers, in puri?ed form, are photolabeled
with nucleotide photoaf?nity probes (Campbell et al,
into a 42 kD protein. The comparative analyses of cere
Proc. Natl. Acad. Sci. 87:1243-1246 (1990); Mann et at,
bral spinal ?uid samples from Alzheimer’s disease pa
Peptide Research 4:79-83 (1991); Shoemaker et al, Pro
tients and from normal human subjects, photolabeled

